Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 25899


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Medical
  • Therapeutic
  • Personal Care Products
  • Hair loss
  • Psoriasis
  • Device

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 25899

License Grant
The Licensee has exercised an option to exclusively License a pending patent entitled, 'Method to Inhibit Proliferation and Growth of Metastases' from a University.
License Property
The resulting devices would inhibit tumor growth by reducing the presence of circulating growth factors without interfering with surgical wound healing or the recovery of tissue injured by radiation therapy. There is a significant unmet clinical need, as other drug agents may not be indicated for use in conjunction with surgical procedures or radiation treatment as they inhibit wound healing and tissue recovery.
Field of Use
The License provides a rapid development strategy for new cancer therapies by uniting drug agents that inhibit the spread of cancer-related metastases, with filtration techniques already proven in the Licensee's Hemopurifier(R).

The rights granted apply to the healthcare industry relating to reducing the presence of infectious viruses from human blood.

IPSCIO Record ID: 25932

License Grant
Our parent company, entered into a royalty Agreement with respect to interferon, transfer factor and products using interferon and transfer factor.
License Property
Interferon is the body’s first defense response to foreign substances such as viruses, interfering with the viral growth and replication processes. Interferons induce anti-viral, anti-tumor and immunomodulatory responses within the body. Clinical studies indicate that interferons may also inhibit malignant cell and tumor growth without affecting normal cell activity.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 28991

License Grant
Licensor grants an exclusive license for the Licensed Technology in the Field, including, without limitation, the patents and patent applications with the right to grant sublicenses, as well as the right of its sublicensees to grant further sublicenses, to make, have made, use, distribute and sell Licensed Products in the Field using the Licensed Technology covered by the Licensed Patent Rights throughout the Territory.
License Property
PTH technologies useful in the treatment of psoriasis and hair loss.

U.S. Patent No. 5,527,772, 5,840,690, 6,066,618

IPSCIO Record ID: 227271

License Grant
The University grants to Licensee:
– the exclusive worldwide license in the Field of Use to use the Patent to manufacture and sell the Product; and,
– the right to grant sublicenses to any Patent licensed exclusively hereunder, provided that any Sublicensee agrees to be bound by the terms and conditions of this Agreement applicable to Sublicensees.

The agreement is exclusive except for the non-exclusive license granted to the U.S. government

License Property
The patents are for Method and Composition for Angiogenesis Inhibition, Generation And Use Of Mab FM155 To Inhibit Angiogenesis and Tumor Growth, and, Generation And Use Of MABXL313 To Inhibit
Angiogenesis And Tumor Growth In Vivo.

2805 60/114,878 January 6, 1999 Method and Composition for Angiogenesis Inhibition

2806 60/114,877 January 6, 1999 Method and Composition for Angiogenesis Inhibition

2908 60/143,581 July 13, 1999 Generation And Use Of Mab FM155 To Inhibit Angiogenesis and Tumor Growth

2909 60/143,534 July 13, 1999 'Generation And Use Of MAB XL313 To Inhibit Angiogenesis And Tumor Growth In Vivo

Anti-Angiogenesis for the Treatment of Cancer

In a process known as angiogenesis, cancer cells stimulate the formation of new blood vessels in order to bring oxygen and nutrients to rapidly-growing tumor tissue. The onset of angiogenesis is caused mainly by tumor cell production of growth factors that activate the cells that line the blood vessels. These activated cells begin to divide and lead to the remodeling of the extracellular matrix, which is a dense protein network that provides support and growth signals for blood vessels and tumors.

Field of Use
Field of Use shall mean any field of use.

IPSCIO Record ID: 1370

License Grant
The Company acquired exclusive worldwide rights to the GliaSite® Radiation Therapy System.

Licensor is willing to grant Licensee rights to the Licensor IP in the Territory with a limited field of use of intracavity radiation therapy (brachytherapy) of the brain (“Exclusive Field of Use”).

License Property
the GliaSite® Radiation Therapy System, the only FDA-cleared balloon catheter device used in the treatment of brain cancer.

GliaSite® Radiation Therapy System (RTS) is for the treatment of brain cancer, i.e. primary and recurrent gliomas and metastic brain tumors.  Specifically, the intended use of GliaSite® RTS is the management of surgically resectable brain tumors where adjuvant radiation therapy of the post-resection tissue bed is indicated.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.